Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib Dose Escalation in Advanced Solid Tumors
NCT02182206Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2003
- Primary completion
- Jun 2005
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in solid tumor, sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose up to 7 months and Adverse Events up to 7 months. Started Jun 2003; status: completed.
02
Drugs
nintedanib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02182206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182206.